Breast Cancer Diagnostics

Global Breast Cancer Diagnostics Market to Reach US$6.9 Billion by 2030

The global market for Breast Cancer Diagnostics estimated at US$4.7 Billion in the year 2024, is expected to reach US$6.9 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Imaging Techniques, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Biopsy segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 10.2% CAGR

The Breast Cancer Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Breast Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Is Early Breast Cancer Detection More Important Than Ever?

Breast cancer remains one of the most prevalent and life-threatening malignancies worldwide, making early detection crucial in improving patient survival rates. Advances in breast cancer diagnostics have significantly enhanced the ability to identify the disease at its earliest stages, allowing for timely interventions and more effective treatment strategies. Traditional diagnostic methods, including mammography, ultrasound, and biopsy, continue to play a pivotal role, but emerging techniques such as liquid biopsies and AI-assisted imaging are rapidly transforming the landscape. Government-backed awareness campaigns and routine screening programs have increased the frequency of early detection, leading to improved survival outcomes. Additionally, the integration of digital health solutions and telemedicine platforms is expanding access to diagnostic services, particularly in remote and underserved regions. As early diagnosis remains the cornerstone of effective breast cancer management, continued advancements in screening technologies are expected to drive market growth.

What Are the Latest Innovations in Breast Cancer Diagnostics?

The field of breast cancer diagnostics is evolving with the introduction of cutting-edge technologies that improve accuracy and reduce false positives. AI-powered imaging analysis, deep-learning algorithms, and machine-learning models are enhancing the precision of mammography and ultrasound interpretations, minimizing human error. Liquid biopsy, a non-invasive diagnostic technique, is gaining traction as an alternative to traditional tissue biopsies by detecting circulating tumor DNA (ctDNA) and tumor-associated markers in blood samples. Furthermore, advancements in 3D tomosynthesis provide high-resolution imaging, improving lesion detection and reducing unnecessary biopsies. Digital pathology and cloud-based diagnostic platforms are also revolutionizing breast cancer diagnostics by enabling remote consultations and seamless data sharing among healthcare providers. As research continues to refine molecular and genetic testing methodologies, these innovative approaches are expected to shape the future of breast cancer diagnostics.

Which Healthcare Sectors Are Leading the Adoption of Breast Cancer Diagnostic Technologies?

The adoption of breast cancer diagnostic tools is widespread across various healthcare sectors, including hospitals, diagnostic imaging centers, pathology laboratories, and specialized breast cancer clinics. Hospitals continue to serve as primary centers for comprehensive breast cancer diagnostics, offering a range of imaging and biopsy procedures under one roof. Diagnostic imaging centers are increasingly equipping themselves with state-of-the-art mammography and MRI systems, catering to the growing demand for precise and non-invasive screening solutions. Pathology laboratories are integrating AI-driven digital pathology tools to enhance the efficiency of tissue analysis and biomarker testing. Moreover, mobile screening units and telehealth services are playing a vital role in extending breast cancer diagnostic services to rural and underserved populations. As healthcare facilities worldwide invest in next-generation diagnostic tools, the accessibility and accuracy of breast cancer detection are expected to improve significantly.

What Factors Are Driving Market Growth?

The growth in the breast cancer diagnostics market is driven by several factors, including advancements in imaging technologies, the increasing prevalence of breast cancer, and rising investments in precision diagnostics. The expansion of AI-powered diagnostic tools and liquid biopsy techniques is enhancing early detection capabilities, allowing for more targeted treatment approaches. Government initiatives promoting breast cancer screening programs and increased healthcare expenditure are further fueling market demand. Additionally, the integration of digital health platforms, wearable breast cancer detection devices, and cloud-based diagnostic solutions is streamlining patient monitoring and data analysis. Pharmaceutical and biotech companies are actively collaborating with research institutions to develop biomarker-based diagnostic tests, improving the accuracy of breast cancer detection. As technology continues to advance, the breast cancer diagnostics market is poised for sustained growth, offering new possibilities for early and more effective disease management.

SCOPE OF STUDY:

The report analyzes the Breast Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Imaging Techniques, Biopsy, Genomic Tests, Blood Tests, Other Types); Product Type (Instrument-based Products, Platform-based Products); Application (Diagnostic and Predictive Application, Screening Application, Prognostic Application, Research Application); End-Use (Hospitals and Clinics End-Use, Diagnostic Centers and Medical Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AstraZeneca PLC
• Becton, Dickinson and Company
• Danaher Corporation
• Devicor Medical Products Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd. (Roche Diagnostics)
• GE HealthCare
• Hologic, Inc.
• Ibex Medical Analytics Ltd.
• Koninklijke Philips N.V.
• NanoString Technologies, Inc.
• Quest Diagnostics Incorporated
• Siemens Healthineers AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.